# Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients

> **NCT01351636** · PHASE4 · COMPLETED · sponsor: **Sumitomo Pharma (Suzhou) Co., Ltd.** · enrollment: 300 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Arotinolol Hydrochloride
- **DRUG:** Non arotinolol group

## Key facts

- **NCT ID:** NCT01351636
- **Lead sponsor:** Sumitomo Pharma (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2018-10-10
- **Final completion:** 2018-10-10
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2019-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01351636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01351636, "Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01351636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*